tetano
Editor, Senior Moderator
Clin Otolaryngol
. 2023 Mar 27.
doi: 10.1111/coa.14056. Online ahead of print.
Effect of the povidone iodine, hypertonic alkaline solution and saline nasal lavage on nasopharyngeal viral load in COVID-19
Aysegul Batioglu-Karaaltin[SUP] 1 [/SUP], Ozgur Yigit[SUP] 2 [/SUP], Dogan Cakan[SUP] 1 [/SUP], Ozer Akgul[SUP] 3 [/SUP], Enes Yigit[SUP] 2 [/SUP], Yetkin Zeki Yilmaz[SUP] 1 [/SUP], Kays-I Burak Cakir[SUP] 1 [/SUP], Gamze Ciftci[SUP] 1 [/SUP], Nihal Seden Boyoğlu[SUP] 2 [/SUP], Abdurrahman Cagliyan[SUP] 2 [/SUP], Efe Can[SUP] 2 [/SUP], Ozgur Dikme[SUP] 4 [/SUP], Yalcin Hacioglu[SUP] 5 [/SUP], Ilker Inanc Balkan[SUP] 6 [/SUP], Ozgur Enver[SUP] 7 [/SUP], Hasan Ahmet Ozdogan[SUP] 1 [/SUP]
Affiliations
Abstract
Objective: The present study aimed to investigate the in vivo activity of nasal irrigation (NI) with saline, NI with povidone-iodine (PVP-I) 1%, NI with a mix of hypertonic alkaline and PVP-I 1% against Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2).
Design: This study was a prospective randomised clinical trial.
Setting: A multicenter study involving tertiary care centres.
Participants: The study included adult outpatients whose qualitative SARS-CoV-2 RT-PCR tests in nasopharyngeal swabs were positive. One hundred twenty patients were divided into four equal groups. Standard COVID-19 treatment was given to Group 1, NI containing saline was added to patients' treatment in Group 2, NI containing 1% PVP-I solution was added to patients' treatment in Group 3, and NI containing 1% PVP-I solution and the hypertonic alkaline solution was added to patients' treatment in Group 4.
Main outcome measures: On the first day of diagnosis (Day 0), nasopharyngeal swab samples were taken, on the third and fifth days the nasopharyngeal viral load (NVL) reduction in quantitative RT-PCR test was calculated.
Results: Between the zeroth to third days and zeroth to fifth days, the NVL reduction was significant in all groups (p < .05). In paired comparisons of groups, the NVL decrease in Group 4 in the first 3 days was significantly lower than all groups (p < .05). The NVL decrease in Groups 3 and 4 in the first 5 days were significantly lower than Group 1 (p < .05).
Conclusion: This study revealed that the use of NI of 1% PVP-I and the hypertonic alkaline solution mixture was more effective in reducing NVL.
Keywords: COVID-19; hypertonic alkaline solution; nasopharyngeal viral load; povidone-iodine.
. 2023 Mar 27.
doi: 10.1111/coa.14056. Online ahead of print.
Effect of the povidone iodine, hypertonic alkaline solution and saline nasal lavage on nasopharyngeal viral load in COVID-19
Aysegul Batioglu-Karaaltin[SUP] 1 [/SUP], Ozgur Yigit[SUP] 2 [/SUP], Dogan Cakan[SUP] 1 [/SUP], Ozer Akgul[SUP] 3 [/SUP], Enes Yigit[SUP] 2 [/SUP], Yetkin Zeki Yilmaz[SUP] 1 [/SUP], Kays-I Burak Cakir[SUP] 1 [/SUP], Gamze Ciftci[SUP] 1 [/SUP], Nihal Seden Boyoğlu[SUP] 2 [/SUP], Abdurrahman Cagliyan[SUP] 2 [/SUP], Efe Can[SUP] 2 [/SUP], Ozgur Dikme[SUP] 4 [/SUP], Yalcin Hacioglu[SUP] 5 [/SUP], Ilker Inanc Balkan[SUP] 6 [/SUP], Ozgur Enver[SUP] 7 [/SUP], Hasan Ahmet Ozdogan[SUP] 1 [/SUP]
Affiliations
- PMID: 36973223
- DOI: 10.1111/coa.14056
Abstract
Objective: The present study aimed to investigate the in vivo activity of nasal irrigation (NI) with saline, NI with povidone-iodine (PVP-I) 1%, NI with a mix of hypertonic alkaline and PVP-I 1% against Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2).
Design: This study was a prospective randomised clinical trial.
Setting: A multicenter study involving tertiary care centres.
Participants: The study included adult outpatients whose qualitative SARS-CoV-2 RT-PCR tests in nasopharyngeal swabs were positive. One hundred twenty patients were divided into four equal groups. Standard COVID-19 treatment was given to Group 1, NI containing saline was added to patients' treatment in Group 2, NI containing 1% PVP-I solution was added to patients' treatment in Group 3, and NI containing 1% PVP-I solution and the hypertonic alkaline solution was added to patients' treatment in Group 4.
Main outcome measures: On the first day of diagnosis (Day 0), nasopharyngeal swab samples were taken, on the third and fifth days the nasopharyngeal viral load (NVL) reduction in quantitative RT-PCR test was calculated.
Results: Between the zeroth to third days and zeroth to fifth days, the NVL reduction was significant in all groups (p < .05). In paired comparisons of groups, the NVL decrease in Group 4 in the first 3 days was significantly lower than all groups (p < .05). The NVL decrease in Groups 3 and 4 in the first 5 days were significantly lower than Group 1 (p < .05).
Conclusion: This study revealed that the use of NI of 1% PVP-I and the hypertonic alkaline solution mixture was more effective in reducing NVL.
Keywords: COVID-19; hypertonic alkaline solution; nasopharyngeal viral load; povidone-iodine.